You don't think the stock can pop a bit if Phase 3 efficacy results are positive?
It definitely can pop with positive efficacy result without much safety concern. If there are some safety signals, it depends on how strongly they are. Remember what the market response was to PFE's supposed safety issue early this year.
The first ph3 result around mid 2012 comes from "A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist" This is the toughest trial besides the long term safety trial - the other two trials with results in 2013 are more likely to be positive IMO. It's not something I would bet on. It definitely can pop if result is positive. A runup play is not a bad idea, with much lower risk.
Market Data 
Markets 
AI
